New cocktail of drugs shows promise for stomach cancer patients
NCT ID NCT07655661
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the combo shrinks tumors and controls the disease. Researchers will also monitor side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mannatide, oxaliplatin, capecitabine, tislelizumab
- What this could lead to
- If it works, this could offer a new first-line treatment option for people with advanced stomach cancer, potentially shrinking tumors and extending life.
- What could go wrong
- This is an early phase 2 trial with only 52 people, no comparison group, and it hasn't started yet. The combination may cause significant side effects and may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?